Lupin, one of the leading pharmaceutical companies in India, announced on January 25 that it has received approval from the United States Food and Drug Administration (USFDA) for its Sevelamer Carbonate Tablets, 800 mg.

The company received USFDA nod to market a generic equivalent of Renvele Tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children six years of age and older with chronic kidney disease on dialysis.

Sevelamer Carbonate Tablets (RLD: Renvele) had estimated annual sales of USD 348 million in the U.S.,  according to IQVIAMAT September 2020).

 Shares of the company gained Rs 2.3, or 0.21%, to settle  at  Rs 1,081.85.  The total volume of shares traded  was  249,783 at  the BSE (Monday).